Phase III trial involved 594 patients across 20 countries Ceralasertib-Imfinzi combo showed no new safety concerns AstraZeneca shares fall 1% after trial results Dec 22 (Reuters) - AstraZeneca (AZN.L) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback